TeneoBio

    OverviewSuggest Edit

    TeneoBio is a biotechnology company, developing biologics, such as human heavy chain antibodies (UniAbs) as therapeutics against cancer, autoimmunity and infectious diseases. The Company also develops products for the treatment of multiple myeloma, prostate cancer, immune disorders and AIDS.

    TypePrivate
    HQNewark, CA, US
    Websiteteneobio.com

    Latest Updates

    Cybersecurity ratingAMore

    Key People/Management at TeneoBio

    Roland Buelow

    Roland Buelow

    Chief Executive Officer, Board Member
    Jonathan MacQuitty

    Jonathan MacQuitty

    Board Member
    Ben Buelow

    Ben Buelow

    Chief Medical Officer
    Stephen Dance

    Stephen Dance

    Chief Financial Officer
    Jeff Bird

    Jeff Bird

    Board Member
    Omid Vafa

    Omid Vafa

    Chief Business Officer
    Show more

    TeneoBio Office Locations

    TeneoBio has an office in Newark
    Newark, CA, US (HQ)
    7999 Gateway Blvd
    Show all (1)

    TeneoBio Financials and Metrics

    Summary Metrics

    TeneoBio investors

    TeneoBio Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    93/100

    SecurityScorecard logo

    TeneoBio Online and Social Media Presence

    Embed Graph

    TeneoBio News and Updates

    Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL

    NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies, reported the Phase I clinical entry and the dosing of patients with the bispecific JNJ-75348780 in a Phase…

    Teneobio Announces FDA Clearance of IND for TNB-585 and Initiation of Phase I Clinical Studies for Metastatic Castrate Resistant Prostate Cancer

    NEWARK, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific T-cell engaging antibody for the treatment of metastatic castrate resistant prostate cancer (mCRPC) wa…

    Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma

    NEWARK, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported initial results of a Phase I trial (https://clinicaltrials.gov/ct2/show/NCT03933735) evaluating TNB-38…

    Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies

    NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four options to commercial licenses for Teneobio human heavy chain only domain antibodies, UniDabs®, to …

    Teneobio Announces the Presentation of Interim Phase I Data on TNB-383B (Anti-BCMAxCD3) at the 62nd Annual Meeting of the American Society of Hematology

    NEWARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today announced the presentation of interim clinical data from its Phase 1 trial evaluating TNB-383B in relapsed…

    Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio

    NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has entered into a research collaboration and commercial license agreement with ArsenalBio for the use of Te…
    Show more

    TeneoBio Blogs

    TeneoFour’s CD38 Inhibitor Rejuvenates Energy Metabolism of Aged Animals

    NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc. and its affiliate TeneoFour, Inc. announced today a Nature Metabolism publication (https://www.nature.com/articles/s42255-020-00298-z) of a proof of concept study by the Chini Laboratory (Mayo Clinic’s campus in Rochester, Minnesota) de…

    Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics

    NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9 therapeutics company, to use Teneobio’s Heavy Chain Antibodies (UniAbs®) for Intellia’s next generation engine…

    Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

    — Kite and Teneobio will Collaborate on Next-Generation Dual-Targeting CAR T Therapies in Multiple Myeloma Utilizing UniAb® Antibodies — April 02, 2020 08:30 AM Eastern Daylight Time SANTA MONICA, Calif. & NEWARK, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and Teneobio, Inc. a…

    Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma

    NEWARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that it has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatmen…

    Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

    GENEVA & NEWARK, Calif.–(BUSINESS WIRE)–Selexis SA and Teneobio, Inc. announced today that they have signed three commercial license agreements (CLAs) for the development of Teneobio’s Human Heavy-Chain Antibodies (UniAbs™), a new class of multi-specific biologics, for the treatment of multiple …

    Teneobio Licenses Oncology Multispecific Product to Janssen

    NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that as a result of its work with scientists from Janssen Research & Development, LLC, Janssen Biotech,…
    Show more

    TeneoBio Frequently Asked Questions

    • Who are TeneoBio key executives?

      TeneoBio's key executives are Roland Buelow, Jonathan MacQuitty and Ben Buelow.

    • Who are TeneoBio competitors?

      Competitors of TeneoBio include WuXi AppTec, Molecular Partners and BioSpecifics Technologies.

    • Where is TeneoBio headquarters?

      TeneoBio headquarters is located at 7999 Gateway Blvd, Newark.

    • Where are TeneoBio offices?

      TeneoBio has an office in Newark.

    • How many offices does TeneoBio have?

      TeneoBio has 1 office.